What is the AI and Automation for Drug Development course about?
Score your own function red, amber or green, find out which part is weakest, and walk into the next budget round able to defend what you want to fix. Built for leaders reviewing deciding what to adopt, in what order, and defending that choice when the budget round asks why this and not that. Each order is checked and updated against the.
What does the AI and Automation for Drug Development cover on the situation this is built for?
Every day, new AI capabilities emerge that claim to accelerate drug discovery. But as the leader responsible, you face a different challenge. You are not evaluating technology for its own sake. You are weighing which capabilities create real advantage in your workflow. Which tools integrate with existing discovery pipelines. Which investments can be defended when asked why this and not that. The.
Who is the AI and Automation for Drug Development course for?
A senior leader in drug development, accountable for the performance and direction of discovery programs using AI and automation. Owns decisions about tool adoption, resource allocation, and workflow integration.
Who is the AI and Automation for Drug Development course not for?
This is not for data scientists building models, procurement officers evaluating vendors, or executives seeking high-level AI trends. It is for the leader who owns the function and must make the call.
What do you take away from the AI and Automation for Drug Development course?
Assess where your drug discovery function stands in AI maturity Identify which AI capabilities create real workflow leverage Build defensible adoption roadmaps aligned to pipeline goals Evaluate integration points across discovery stages Lead AI strategy without relying on vendor narratives.
How does this map to your situation?
Assessing current AI integration depth Identifying high-leverage AI adoption points Aligning AI with regulatory and team workflows Sustaining AI advantage through iteration.
What's included with your purchase?
12 modules with 12 chapters each (144 chapters) Downloadable templates and worked examples for every module Hand-built implementation playbook delivered alongside course access 30-day money-back guarantee.
What does the AI and Automation for Drug Development cover on delivery and format?
Format: Text-based modules and chapters in the Art of Service learning environment, plus downloadable templates and worked examples for every chapter, plus the hand-built implementation playbook delivered alongside course access. Time investment: Approximately 3 hours per module, designed for completion over 12 weeks with team application exercises.
Closely related courses: AI and Automation Leadership for Drug Development, AI-Driven Drug Discovery and Development, "Data-Driven Drug Development, Unlocking Life-Saving Treatments.
More answers: what you get with every course, refund policy, all help answers.
The Executive Diagnostic and Governance Toolkit
AI and Automation for Drug Development Leaders
Score your own function red, amber or green, find out which part is weakest, and walk into the next budget round able to defend what you want to fix. Built for leaders reviewing deciding what to adopt, in what order, and defending that choice when the budget round asks why this and not that.
Each order is checked and updated against the latest insights before delivery. That is why access takes up to 24 hours rather than being instant.
| 1 |
You stop guessing where you stand. You finish with a score, not an opinion: every part of your function rated red, amber or green, with the weakest ranked first. Evidence: a Quick Scan for the shape of it, then seven domain assessments of 30 scored questions each, 210 in all, rolled into one scorecard, plus a maturity radar and a current-versus-target gap analysis. |
| 2 |
You can defend the decision. You walk into the budget round with the gap named, the owner named and done defined, instead of a case built on instinct. Evidence: project charter, scope statement, RACI, requirements traceability and work breakdown structure, pre-filled in your domain's language. |
| 3 |
The work actually moves. The month after the decision is already built, so nothing stalls waiting for someone to design a form. Evidence: more than 60 project templates across all five PMBOK process groups, plus runbooks, SOPs, a KPI framework, audit checklists and a risk matrix. 55 to 65 files in total. |
| 4 |
You use it the day it lands. No blank templates to interpret. Every workbook opens with what it is, who uses it, when, how, a 1 to 5 scoring guide, what good looks like, and a worked example you delete and type over. |
The situation this is built for
Every day, new AI capabilities emerge that claim to accelerate drug discovery. But as the leader responsible, you face a different challenge. You are not evaluating technology for its own sake. You are weighing which capabilities create real advantage in your workflow. Which tools integrate with existing discovery pipelines. Which investments can be defended when asked why this and not that. The cost of misalignment is high: wasted budget, delayed timelines, and lost credibility. You need a way to assess objectively, act decisively, and lead with clarity.
Who this is for
A senior leader in drug development, accountable for the performance and direction of discovery programs using AI and automation. Owns decisions about tool adoption, resource allocation, and workflow integration.
Who this is not for
This is not for data scientists building models, procurement officers evaluating vendors, or executives seeking high-level AI trends. It is for the leader who owns the function and must make the call.
What you walk away with
- Assess where your drug discovery function stands in AI maturity
- Identify which AI capabilities create real workflow leverage
- Build defensible adoption roadmaps aligned to pipeline goals
- Evaluate integration points across discovery stages
- Lead AI strategy without relying on vendor narratives
How this maps to your situation
- Assessing current AI integration depth
- Identifying high-leverage AI adoption points
- Aligning AI with regulatory and team workflows
- Sustaining AI advantage through iteration
Before vs. after
What's included with your purchase
- 12 modules with 12 chapters each (144 chapters)
- Downloadable templates and worked examples for every module
- Hand-built implementation playbook delivered alongside course access
- 30-day money-back guarantee
Delivery and format
- Course and learning environment access provisioned within 24 hours of purchase
- Hand-built implementation playbook delivered alongside course access
Format: Text-based modules and chapters in the Art of Service learning environment, plus downloadable templates and worked examples for every chapter, plus the hand-built implementation playbook delivered alongside course access.
Time investment: Approximately 3 hours per module, designed for completion over 12 weeks with team application exercises.
How this compares to the alternatives
Unlike vendor-led training or academic courses, this program focuses exclusively on the leader's role in assessing and integrating AI into existing drug discovery workflows, with no promotional content or theoretical focus.
Also included: the full course, for when you want the reasoning behind a finding (12 modules, 144 chapters)
Depth reference. The diagnostic and the templates stand on their own; this is what to read when you want the reasoning behind a finding.
- Identifying all active AI-supported workflows in discovery
- Documenting current automation touchpoints in lead optimization
- Assessing integration of AI tools with CRO partnerships
- Evaluating data flow between experimental and predictive systems
- Cataloging internal AI model development efforts
- Measuring frequency of AI-generated hypothesis testing
- Reviewing validation protocols for AI-driven predictions
- Tracking AI use in preclinical safety assessment
- Auditing computational resource allocation for AI tasks
- Mapping AI tool ownership across discovery teams
- Assessing documentation standards for AI-generated results
- Benchmarking current AI adoption against peer pipelines
- Locating bottlenecks where AI accelerates target identification
- Evaluating AI impact on compound synthesis prioritization
- Identifying stages where prediction reduces lab experimentation
- Assessing AI value in polypharmacology prediction
- Mapping where automation frees medicinal chemist time
- Determining AI utility in toxicity pathway modeling
- Prioritizing AI use in pharmacokinetic forecasting
- Measuring AI contribution to scaffold hopping success
- Aligning AI capabilities with clinical failure mode analysis
- Quantifying time savings in hit-to-lead transitions
- Assessing AI role in multi-omics data integration
- Defining decision gates where AI input is required
- Matching AI output formats to team decision processes
- Evaluating AI tool integration with electronic lab notebooks
- Assessing compatibility with internal data governance rules
- Testing AI model inputs against available assay data
- Reviewing AI system requirements for IT infrastructure
- Checking AI tool alignment with target product profiles
- Evaluating explainability features for regulatory readiness
- Assessing AI vendor collaboration models with discovery teams
- Mapping AI prediction frequency to project timelines
- Reviewing alerting mechanisms for out-of-range predictions
- Evaluating AI support for iterative hypothesis refinement
- Assessing model update cycles against discovery cadence
- Auditing availability of high-quality phenotypic screening data
- Assessing standardization of assay metadata across programs
- Evaluating data lineage tracking for model training sets
- Measuring consistency of chemical structure annotation
- Reviewing historical data completeness for retrospective modeling
- Assessing batch effect documentation in screening datasets
- Evaluating data access controls for AI training use
- Mapping data ownership across therapeutic areas
- Assessing data labeling rigor for supervised learning
- Reviewing data refresh cycles for dynamic model training
- Evaluating data versioning practices for reproducibility
- Assessing real-world data integration potential
- Aligning AI adoption milestones with IND timelines
- Sequencing AI integration by therapeutic area urgency
- Prioritizing AI use in first-in-class versus me-too programs
- Building quarterly review gates for AI performance
- Mapping AI rollout to team reskilling capacity
- Defining success metrics for AI pilot phases
- Integrating AI milestones into portfolio reviews
- Scheduling AI evaluation points with CRO partners
- Aligning AI investment with patent strategy windows
- Building fallback plans for AI prediction failures
- Documenting assumptions behind AI adoption timelines
- Linking AI roadmap to regulatory submission planning
- Designing AI results presentation for project teams
- Setting thresholds for AI-driven compound prioritization
- Incorporating AI confidence scores into decision logs
- Training chemists to interpret model uncertainty bands
- Establishing review protocols for AI outlier predictions
- Integrating AI forecasts into stage-gate documentation
- Defining escalation paths for conflicting AI and lab data
- Scheduling AI re-evaluation after new experimental data
- Building AI input summaries for portfolio committee
- Documenting AI influence on go-no-go decisions
- Creating templates for AI-assisted SAR analysis
- Standardizing language for AI-generated hypotheses
- Measuring reduction in cycles for lead optimization
- Tracking AI impact on compound attrition rates
- Evaluating time saved in dose-response curve analysis
- Assessing AI contribution to reducing false positives
- Monitoring changes in medicinal chemistry iteration speed
- Measuring AI effect on preclinical package completeness
- Tracking reduction in animal testing through prediction
- Evaluating AI impact on clinical trial design inputs
- Assessing speed of target validation with AI support
- Measuring accuracy of AI-forecasted developability issues
- Tracking changes in hit confirmation timelines
- Evaluating AI role in reducing late-stage failures
- Defining model retraining triggers based on new data
- Establishing version control for predictive algorithms
- Setting model validation requirements for IND-enabling studies
- Creating audit trails for model decision pathways
- Documenting model decay monitoring procedures
- Setting thresholds for model performance degradation
- Building model retirement criteria into workflows
- Assigning model stewardship roles across teams
- Scheduling regular model performance reviews
- Integrating model updates with lab protocol changes
- Defining data drift detection mechanisms
- Creating model lineage documentation standards
- Adapting AI tools for oncology target discovery workflows
- Customizing AI models for immunology program needs
- Transferring AI practices to rare disease discovery teams
- Standardizing AI integration across external partners
- Building shared AI infrastructure for multiple programs
- Creating cross-therapeutic area model validation panels
- Establishing AI governance for decentralized teams
- Developing training programs for AI adoption at scale
- Setting common data standards for AI across pipelines
- Managing AI resource allocation across competing programs
- Building templates for AI use in orphan drug development
- Coordinating AI strategy with global regulatory requirements
- Documenting AI use in preclinical study design
- Building regulatory-grade model validation packages
- Ensuring AI traceability for IND submissions
- Preparing model explanation packages for reviewers
- Aligning AI development with ALCOA+ data principles
- Incorporating AI into CMC documentation workflows
- Training regulatory affairs staff on AI outputs
- Mapping AI use to ICH guideline applicability
- Creating audit readiness packages for AI systems
- Defining roles for AI in benefit-risk assessments
- Building inspection response plans for AI tools
- Ensuring AI compliance with 21 CFR Part 11
- Communicating AI strategy to medicinal chemistry leads
- Building trust in AI predictions among experimental teams
- Redesigning roles to incorporate AI oversight duties
- Creating feedback loops between AI developers and biologists
- Managing resistance to AI-driven decision changes
- Incentivizing cross-functional AI collaboration
- Developing AI literacy programs for senior scientists
- Revising performance metrics to include AI fluency
- Establishing forums for AI challenge discussion
- Celebrating AI-enabled discovery milestones
- Addressing concerns about AI and job roles
- Building psychological safety for AI error reporting
- Scheduling quarterly AI capability reassessments
- Updating AI roadmaps based on pipeline performance
- Revising integration plans after platform changes
- Tracking emergence of new AI application areas
- Assessing AI model performance over time
- Reviewing data strategy in light of new AI tools
- Evaluating AI cost-benefit ratios annually
- Updating training programs with new AI capabilities
- Benchmarking against external AI adoption trends
- Adjusting governance for scaled AI use
- Revising risk assessment for AI dependency
- Planning for next-generation AI integration
Frequently asked
Within 24 hours your account in the learning environment is provisioned and the tailored implementation playbook is delivered alongside it.
Thousands of organisations have bought from The Art of Service since 2000.